Urodynamic Evaluation of the Efficacy of Mirabegron on Storage and Voiding Functions in Women With Overactive Bladder
Urodynamic Evaluation of the Efficacy of Mirabegron on Storage and Voiding Functions in Women With Overactive Bladder
复制标题
DOI：
10.1016/j.urology.2015.01.002
复制
发表时间：
2015-04-01
期刊：
影响因子：
2.1
通讯作者：
Gotoh, Momokazu
中科院分区：
文献类型：
--
作者：
Matsukawa, Yoshihisa;Takai, Shun;Gotoh, Momokazu
目的 基于尿动力学研究，探讨米拉贝隆（50 mg，每日一次，持续 12 周）对初治膀胱过度活动症 (OAB) 女性的影响。 方法 这是一项开放标签、单中心、前瞻性研究，纳入了 65 名门诊患者。 OAB症状评分用于评估主观症状的严重程度。进行尿动力学研究，包括尿流测定、膀胱测压和压力流研究，以评估客观症状。将首次排尿意愿、最大膀胱测压能力和逼尿肌过度活动的发生情况作为储存功能参数进行测量，而最大流量、Qmax 时的逼尿肌压力和排尿后残余尿量作为排尿功能参数进行评估。 结果 总共 60 名平均年龄为 72.3 岁（50-86 岁）的患者纳入分析。主观症状参数（即平均OAB症状评分）从9.4分显着下降至6.2分（P
OBJECTIVE To investigate the effects of mirabegron (50 mg once daily for 12 weeks) in treatment-naive women with overactive bladder (OAB) based on urodynamic studies.METHODS This was an open-labeled, single-center, prospective study involving 65 recruited outpatients. The OAB symptom score was used for assessing the severity of subjective symptoms. Urodynamic studies, including uroflowmetry, cystometry, and pressure flow study, were conducted to evaluate objective symptoms. The first desire to void, maximum cystometric capacity, and occurrence of detrusor overactivity were measured as storage function parameters, whereas maximum flow rate, detrusor pressure at Qmax, and postvoid residual urine volume were assessed as voiding function parameters.RESULTS A total of 60 patients with a mean age of 72.3 years (50-86 years) were included in the analysis. The subjective symptom parameter (ie, the mean OAB symptom score) decreased significantly from 9.4 to 6.2 points (P